ArticleBioengineering (Basel, Switzerland)2026
A Scalable Bioreactor Platform for Reproducible Production and Characterization of Ovarian Cancer-Derived Extracellular Vesicles.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Extracellular vesicles (EVs) from ovarian cancer cells are valuable sources for candidate biomarker studies, but conventional static flask culture yields limited material and is difficult to scale reproducibly. We evaluated a serum-free CELLine AD 1000 bioreactor workflow for producing EVs from four ovarian cancer-related (OC-related) cell lines (OVCAR4, CaOV3, PA1, SW626) and human dermal fibroblasts (HDFa) as a non-cancer control. Cells were adapted to CDM-HD serum-free medium and maintained for eight weeks with twice-weekly conditioned-medium collection. EVs were isolated by differential ultracentrifugation followed by size-exclusion chromatography and characterized by nanoparticle tracking analysis, imaging flow cytometry, Western blotting, and transmission and scanning electron microscopy. Across longitudinal harvests, OC-related cultures generally produced higher EV particle concentrations and A280-based bulk protein estimates than HDFa, while individual cell lines showed distinct production profiles and membrane-associated growth patterns. A parallel OVCAR4 T-175 flask, maintained in its original serum-containing medium, provided a contextual reference indicating higher per-collection EV particle recovery with the bioreactor, although this was not a matched culture-format comparison. EV-enriched preparations contained vesicle-like particles, with modal diameters of approximately 96-128 nm. Using imaging flow cytometry, the CD9 signal was higher in OC-related EVs and CD63 was most prominent in HDFa; CD9 and CD63 were also detected in OC-related EV lysates by Western blotting. Because one bioreactor was operated per cell line, these findings should be interpreted as preliminary and descriptive rather than statistically comparative. Overall, this study provides a practical serum-free CELLine AD 1000 workflow for generating characterized OC-related EV material for downstream analytical studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.